Who holds NovaBay Pharmaceuticals'stock?
Only 1.80% of the stock of NovaBay Pharmaceuticals is held by insiders. Only 2.59% of the stock of NovaBay Pharmaceuticals is held by institutions. Earnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($0.21) to ($0.09) per share.
How much money does NovaBay make a year?
NovaBay Pharmaceuticals has a market capitalization of $21.74 million and generates $9.93 million in revenue each year. The biopharmaceutical company earns $-11.03 million in net income (profit) each year or ($0.17) on an earnings per share basis. How many employees does NovaBay Pharmaceuticals have?
Who is on the NovaBay Board of directors?
EMERYVILLE, Calif., January 28, 2022--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing high-quality, scientifically formulated products for the eyecare and skincare markets, announces the appointments of Audrey Kunin, M. D. and Julie Garlikov to the NovaBay Board of Directors.
Where can I buy shares of NBY?
Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
See more
Is NBY stock a buy right now?
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last twelve months. There are curr...
Will NovaBay Pharmaceuticals' stock price go up in 2022?
1 Wall Street analysts have issued twelve-month price targets for NovaBay Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On av...
How has NovaBay Pharmaceuticals' stock performed in 2022?
NovaBay Pharmaceuticals' stock was trading at $0.3053 on January 1st, 2022. Since then, NBY stock has decreased by 25.7% and is now trading at $0.2...
How were NovaBay Pharmaceuticals' earnings last quarter?
NovaBay Pharmaceuticals, Inc. (NYSE:NBY) announced its quarterly earnings data on Tuesday, March, 29th. The company reported ($0.02) earnings per s...
Who are NovaBay Pharmaceuticals' key executives?
NovaBay Pharmaceuticals' management team includes the following people: Mr. Justin M. Hall Esq. , Pres, CEO, Gen. Counsel, Chief Compliance Offic...
Who are some of NovaBay Pharmaceuticals' key competitors?
Some companies that are related to NovaBay Pharmaceuticals include Eledon Pharmaceuticals (ELDN) , Larimar Therapeutics (LRMR) , Neoleukin Thera...
What other stocks do shareholders of NovaBay Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include OpGen (OPGN)...
What is NovaBay Pharmaceuticals' stock symbol?
NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "NBY."
How do I buy shares of NovaBay Pharmaceuticals?
Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull...
Is NBY stock a buy right now?
1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last twelve months. There...
Will NovaBay Pharmaceuticals' stock price go up in 2022?
1 Wall Street research analysts have issued twelve-month price objectives for NovaBay Pharmaceuticals' stock. Their forecasts range from $2.20 to $...
How has NovaBay Pharmaceuticals' stock performed in 2022?
NovaBay Pharmaceuticals' stock was trading at $0.3027 at the beginning of the year. Since then, NBY stock has decreased by 24.0% and is now trading...
How were NovaBay Pharmaceuticals' earnings last quarter?
NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) announced its quarterly earnings data on Tuesday, March, 29th. The biopharmaceutical company repor...
When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?
NovaBay Pharmaceuticals's stock reverse split on the morning of Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, Decembe...
Who are NovaBay Pharmaceuticals' key executives?
NovaBay Pharmaceuticals' management team includes the following people: Mr. Justin M. Hall Esq. , Pres, CEO, Gen. Counsel, Chief Compliance Offic...
Who are some of NovaBay Pharmaceuticals' key competitors?
Some companies that are related to NovaBay Pharmaceuticals include NexImmune (NEXI) , Tyme Technologies (TYME) , Larimar Therapeutics (LRMR) ,...
What other stocks do shareholders of NovaBay Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zent...
What is NovaBay Pharmaceuticals' stock symbol?
NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions
NovaBay Pharmaceuticals, Inc. engages in development of products for eye care. Its products include Avenova, NeutroPhase, and CelleRx. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.
AMEX
1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock.
Environmental, Social, and Governance Rating
NovaBay Pharmaceuticals Inc. is a clinical stage pharmaceutical Company engaged in the discovery and development of innovative product candidates for the treatment or prevention of a range of infections in hospital and non-hospital environments.
Business Summary
"A" score indicates excellent relative ESG performance and a high degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
